<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113266</url>
  </required_header>
  <id_info>
    <org_study_id>Junshi-JS001-009</org_study_id>
    <nct_id>NCT03113266</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma</brief_title>
  <official_title>A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody&#xD;
      JS001, as a monotherapy in patients with locally advanced or metastatic bladder urothelial&#xD;
      carcinoma who have failed in routine systemic treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody&#xD;
      JS001, as a monotherapy in patients with locally advanced or metastatic bladder urothelial&#xD;
      carcinoma who have failed in routine systemic treatment.The implementation of study meet the&#xD;
      GCP.370 patients will be enrolled in the study to evaluate the safety and efficacy of&#xD;
      JS001.Patients are injected with JS001 with 3mg/kg every 2 weeks until disease progresses or&#xD;
      unacceptable toxicity occurs.Response assessment is conducted by every 8 weeks in first year,&#xD;
      every 12 weeks in second year and every 16 weeks in third year and beyond.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">March 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) by RECIST 1.1 and irRECIST</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine tumor response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) by RECIST1.1 and irRECIST</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine duration of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) by RECIST1.1 and irRECIST</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine progression-free survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The treatment effect of JS001 will be assessed using irRC and RECIST 1.1 to determine overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of anti-PD-1 monoclonal antibody</measure>
    <time_frame>3 years</time_frame>
    <description>To test immunogenicity of anti-PD-1 monoclonal antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation analysis of PD-L1 expression of tumor by ORR</measure>
    <time_frame>3 years</time_frame>
    <description>correlation analysis of PD-L1 expression of tumor and objective response rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation analysis of PD-L1 expression of tumor by Immunohistochemistry</measure>
    <time_frame>3 years</time_frame>
    <description>to analyse PD-L1 expression of tumor by Immunohistochemistry</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Bladder Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>humanized anti-PD-1monoclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>humanized anti-PD-1 monoclonal antibody toripalimab</intervention_name>
    <description>humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.</description>
    <arm_group_label>humanized anti-PD-1monoclonal antibody</arm_group_label>
    <other_name>JS001, TAB001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female aged 18 and older are eligible;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;&#xD;
&#xD;
          -  Histologic diagnosis of locally advanced or metastatic bladder urothelial carcinoma,&#xD;
             including the origin of renal pelvis, ureter, urinary tract;&#xD;
&#xD;
          -  At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded)&#xD;
             (routine CT scan &gt;=20mm, spiral CT scan &gt;=10mm, no prior radiation to measurable&#xD;
             lesions);&#xD;
&#xD;
          -  Providing with tumor specimen (for testing the expression of PD -L1 and the&#xD;
             infiltrating lymphocytes);&#xD;
&#xD;
          -  Predicted survival &gt;=3 months;&#xD;
&#xD;
          -  Brain or meningeal metastases must be disposed with surgery or radiation, and be&#xD;
             stable clinically for at least 3 months (prior systemic steroids was allowed, but&#xD;
             concurrent administration of systemic steroids with the study drug is excluded).&#xD;
&#xD;
          -  Screening laboratory values must meet the following criteria（within past 14 days）:&#xD;
&#xD;
        hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ µL; platelets ≥ 100 x 10^3/ µL; total&#xD;
        bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine&#xD;
        transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum&#xD;
        creatinine ≤1╳ULN，creatinine clearance &gt;50ml/min (Cockcroft-Gault equation) INR, aPTT≤1.5 x&#xD;
        ULN; Urine protein + 1 or less, if the urine protein &gt; 1 +, need to collect 24 hours&#xD;
        urinary protein determination, the total amount should be 1 gram or less&#xD;
&#xD;
          -  Without systemic steroids within past 4 weeks&#xD;
&#xD;
          -  Males or female of childbearing potential must: agree to use using a reliable form of&#xD;
             contraception (eg, oral contraceptives, intrauterine device, control sex desire,&#xD;
             double barrier method of condom and spermicidal) during the treatment period and for&#xD;
             at least 12 months after the last dose of study drug.&#xD;
&#xD;
          -  Must have read, understood, and provided written informed consent voluntarily. Willing&#xD;
             to adhere to the study visit schedule and the prohibitions and restrictions specified&#xD;
             in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with anti-PD-1/PD-L1/PD-L2 antibody, including auxiliary treatment&#xD;
             phase&#xD;
&#xD;
          -  Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Abm or its components&#xD;
&#xD;
          -  Prior antitumor therapy (including corticosteroids and immunotherapy) or participation&#xD;
             in other clinical trials within past 4 weeks, or have not recovered from toxicities&#xD;
             since the last treatment;&#xD;
&#xD;
          -  Pregnant or nursing;&#xD;
&#xD;
          -  Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA&#xD;
             (&gt;500IU/ml);&#xD;
&#xD;
          -  HBsAg or HBcAb with positive test for HBV DNA (&gt;500IU/ml)&#xD;
&#xD;
          -  History with active tuberculosis;&#xD;
&#xD;
          -  Patients with any active autoimmune disease or a documented history of autoimmune&#xD;
             disease, or history of syndrome that required systemic steroids or immunosuppressive&#xD;
             medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis,&#xD;
             hyperthyroidism or hypothyroidism;&#xD;
&#xD;
          -  Severe, uncontrolled medical condition that would affect patients' compliance or&#xD;
             obscure the interpretation of toxicity determination or adverse events, including&#xD;
             active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure &gt;&#xD;
             class II NYHA, heart block &gt;II grade, myocardial infarction, unstable arrhythmia or&#xD;
             unstable angina within past 6 months, cerebral infarction within past 3 months) or&#xD;
             pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or&#xD;
             symptomatic bronchospasm);&#xD;
&#xD;
          -  Evidence with active CNS disease;&#xD;
&#xD;
          -  Prior live vaccine therapy within past 4 weeks;&#xD;
&#xD;
          -  Received allogeneic hematopoietic stem cell transplantation or solid organ&#xD;
             transplantation;&#xD;
&#xD;
          -  Prior major surgery within past 4 weeks (diagnostic surgery excluded);&#xD;
&#xD;
          -  Psychiatric medicines abuse without withdrawal, or history of psychiatric illness;&#xD;
&#xD;
          -  Associated with clinical symptoms or symptomatic treatment of pleural effusion or&#xD;
             ascites;&#xD;
&#xD;
          -  Prior malignancy active within the previous 5 years except for locally curable cancers&#xD;
             that have been apparently cured, such as basal cell skin cancer or carcinoma in situ&#xD;
             of the cervix.&#xD;
&#xD;
          -  Underlying medical condition that, in the Investigator's opinion, would increase the&#xD;
             risks of study drug administration or obscure the interpretation of toxicity&#xD;
             determination or adverse events.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Xiao</last_name>
    <phone>051286876925</phone>
    <email>ling_xiao@topalliancebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, Phd; Md</last_name>
      <email>guoj307@126.com</email>
    </contact>
    <investigator>
      <last_name>Jun Guo, PhD; MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-PD-1 monoclonal antibody</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Advanced</keyword>
  <keyword>Bladder Urothelial Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

